{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1013","value":"-0.007"},{"groupId":"OG001","spread":"0.1015","value":"-0.011"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: \"no problems\" (Level 1), \"slight problems\" (Level 2), \"moderate problems\" (Level 3), \"severe problems\" (Level 4), and \"extreme problems\" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEAN","populationDescription":"Intent-to-treat Population. Only those participants with data available at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)","title":"Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}